Impact of heparin neutralization by protamine on restenosis after coronary stent implantation.
Kaneda
Hideaki
H
Suzuki
Jun
J
Hosokawa
George
G
Tanaka
Shinji
S
Hiroe
Yoshitaka
Y
Saito
Shigeru
S
D000368:Aged; D000787:Angina Pectoris / Q000628:therapy; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects; D023903:Coronary Restenosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006494:Heparin Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011479:Protamines / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects; D013988:Ticlopidine / Q000627:therapeutic use; D016896:Treatment Outcome
D000925:Anticoagulants; D006494:Heparin Antagonists; D010975:Platelet Aggregation Inhibitors; D011479:Protamines; D006493:Heparin; D013988:Ticlopidine; D001241:Aspirin